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“Love is like oxygen: 
You get too much you get too high  
Not enough and you’re gonna die.”  
The Sweet, 1978 
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ABSTRACT 
 
Background  
Oxygen therapy has been used routinely in patients with suspected acute myocardial 
infarction (AMI) for more than a hundred years. Even today, supplemental oxygen is widely 
recommended in guidelines and implemented in clinical practice, despite limited data 
supporting a beneficial clinical effect.  
The overall objective of the present thesis was to clarify the role of routine oxygen therapy in 
AMI. After testing logistics, feasibility and safety in a pilot study, a nationwide registry-based 
randomized clinical trial (RRCT) concept was used to evaluate hard clinical endpoints. In a 
subgroup of patients, biomarkers were used to get insights on aspects of underlying 
pathophysiology. 
 
Methods and results 
Study I was a pilot study at Södersjukhuset. One hundred twenty-nine normoxemic patients 
with suspected AMI were randomized 1:1 to either oxygen therapy at 6 L/min delivered by 
open face mask for 12 hours or ambient air. A total of 81 (63%) patients were diagnosed with 
AMI. No unexpected logistical or notable medical problems occurred. Oxygen therapy for 12 
hours was well tolerated.  
Study II was a nationwide, multicenter, prospective, registry-based randomized clinical trial 
(RRCT) using a public quality registry for coronary care (SWEDEHEART) for trial 
procedures and evaluating the primary outcome – all-cause mortality at one year – through 
national health registries. Patients with suspected AMI and oxygen saturation of 90% or 
above were randomly assigned to either supplemental oxygen at 6 L/min for 6-12 hours 
delivered by open face mask or ambient air. A total of 6,629 patients were enrolled from 
April 2013 through December 2015. No patients were lost to follow-up. The primary 
endpoint death from any cause at 1-year occurred in 5.0% (166 of 3,311) of patients in the 
oxygen group compared to 5.1% (168 of 3,318) in the ambient-air group (hazard ratio 0.97; 
95% confidence interval, 0.79 – 1.21; p=0.8). The results were consistent across all 
predefined subgroups.  
Study III was a prespecified two-center substudy to study II. One hundred forty-four patients 
were consecutively recruited after randomization and blood samples were secured at 
randomization and 5-7 hours after. Ninety-two inflammatory biomarkers, using proximity 
extension assay technology, were analyzed to evaluate the effect of oxygen on the systemic 
inflammatory response to AMI. The inflammatory response did not differ between the two 
treatment groups, neither did plasma troponin T levels. After adjustment for increase in 
  
troponin T over time, age, and sex, the release of inflammation-related biomarkers was still 
similar in the groups. 
 
Summary and conclusions 
In summary, study I found the design of the DETO2X-AMI-trial to be robust and feasible. 
Implemented inclusion criteria identified patients with acute cardiac disease with a high 
proportion of acute myocardial infarctions among the study population. 
Study II demonstrated that the routine use of supplemental oxygen in patients with suspected 
AMI without hypoxemia at presentation did not reduce 1-year all-cause mortality. Neither did 
it affect the incidence of rehospitalization with myocardial infarction or the size of 
myocardial injury as assessed by highly sensitive cardiac troponin T. 
Study III showed that the use of supplemental oxygen did not have any impact on the early 
release of systemic inflammatory markers.  
In conclusion, we were able to build up a study system and nationwide network based on the 
SWEDEHEART registry. Thereby, we managed to recruit many eligible patients within a 
short time frame, delivering high quality data at relatively low cost. Normoxemic patients 
with suspected AMI did not benefit from routine oxygen therapy when assessing 1-year all-
cause mortality. Although our findings do not support the general use of oxygen in the 
normoxemic patient with suspected AMI, there nevertheless remains the risk to develop 
hypoxemia which must be detected and treated immediately. Furthermore, even though we 
could not demonstrate deleterious effects of routine oxygen treatment, there might be a dose-
dependent relationship and inadvertent hyperoxemia should be avoided. 
 
Key words 
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1 RESEARCH QUESTION AND RATIONALE 
 
Coronary artery disease (CAD) with its feared primary presentation as acute myocardial 
infarction (AMI) remains the prominent cause of morbidity and mortality in the world.1  AMI 
is caused by acute coronary syndrome (ACS) which describes plaque rupture and subsequent 
coronary thrombosis leading to either subtotal coronary occlusion and Non-ST-Elevation 
Myocardial Infarction (NSTEMI) or acute total occlusion of the vessel and ST-Elevation 
Myocardial Infarction (STEMI). Modern medical reperfusion strategies and acute 
percutaneous coronary intervention (PCI) with stent implantation have improved prognosis 
immensely.2-5 
 
Supplemental oxygen has been administered in the setting of suspected AMI in pre-hospital 
and hospital clinical routine across the world for over a century6 and is still manifested today 
in international treatment guidelines.7,8 This recommendation is based on the belief that 
reduced coronary blood flow leads to diminished delivery of oxygen to the threatened 
myocardium and, therefore, an imbalance between myocardial oxygen demand and supply. 
The administration of supplemental oxygen is intended to optimize oxygen delivery to the 
ischemic heart muscle with the goal of reducing infarct size9,10 as well as potential 
complications such as heart failure and malignant arrhythmias.  
However, this common practice has been challenged lately which brings into question the 
scientific evidence for such a ubiquitous therapy.11 Considerable data suggest that oxygen 
therapy may lead to negative cardiovascular hemodynamics and possibly detrimental effects 
concerning myocardial injury and, ultimately, survival.  
In summary, the existing scientific evidence is inconsistent and fails to resolve the role of 
oxygen therapy in patients with acute ischemic heart disease. The need to clarify this 
important issue is urgent.  
With the DETermination of the role of OXygen in suspected Acute Myocardial Infarction 
(DETO2X) trial series presented in this thesis, we aimed to add substantial knowledge to 
determine the role of routine oxygen therapy in AMI. By building up a nationwide trial 
alliance for a large randomized clinical trial we could evaluate hard clinical endpoints. 
Underlying pathophysiology was assessed in a biomarker analysis in a subgroup of patients. 
 
Introduction 
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2 INTRODUCTION 
 
2.1 CORONARY ARTERY DISEASE AND ACUTE MYOCARDIAL INFARCTION 
 
2.1.1 Pathogenesis and clinical classification  
The current understanding of the pathogenesis of CAD and AMI was first established in 
1970.12 It was shown that the formation of blood clots in a coronary artery was caused by the 
exposure of prothrombotic material through the acute rupture or erosion of a focal 
calcification or plaque. The subsequent narrowing of the vessel in combination with distal 
embolization of thrombotic material leads to partial or total obstruction of blood flow to the 
heart muscle and, ultimately, myocardial infarction.  
Hemodynamically, the flow-limiting narrowing of the vessel diameter causes clinical 
symptoms of angina based on a mismatch of myocardial perfusion and metabolic demand. 
The degree and duration of ischemia and subsequently the level of myocardial necrosis, is 
determined by the severity of pre-existing stenosis, extent and persistence of the thrombus, 
degree of concomitant vasoconstriction, presence of collaterals, and the myocardial perfusion 
demand.13,14 
The clinical picture is commonly graded as follows: 
1. Stable angina15 
Reversible angina symptoms caused by exertion – No myocardial damage 
Acute coronary syndrome encompassing: 
2. Unstable angina7 
New onset or sudden worsening of previously stable symptoms that arise more often 
with less exertion or even at rest due to temporary thrombi with partial/intermittent 
occlusion. No myocardial damage. 
3. Non-ST-elevation myocardial infarction (NSTEMI)7 
Permanent thrombi leading to partial/intermittent occlusion and myocardial damage 
4. ST-elevation myocardial infarction (STEMI)8  
Permanent thrombi leading to total occlusion of a coronary artery and myocardial 
damage. 
The Universal definition of myocardial infarction classifies myocardial necrosis according to 
a clinical setting consistent with acute myocardial ischemia.16 An increase and/or decrease of 
a cardiac biomarker in combination with typical symptoms of ischemia, or new significant 
ECG changes, or imaging evidence of myocardial damage, or intracoronary thrombus on 
angiography or autopsy is required to confirm diagnosis. 
Introduction 
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Since the early 1990s, this complex clinical picture is known as acute coronary syndrome.17,18 
According to the pathogenesis, AMIs are thereafter typed into spontaneous AMI due to ACS 
(type 1), AMI secondary to ischemic imbalance (type 2), AMI resulting in death when 
biomarkers are not available (type 3), AMI related to PCI (type 4), and AMI related to 
coronary artery bypass grafting (CABG) (type 5). 
 
2.1.2 The systemic inflammatory response to acute myocardial infarction 
Today, it is recognized that atherosclerosis is caused by a chronic inflammation in the vessel 
wall over a lifetime19 in response to biological effects of risk factors.20,21 
The inflammatory response to myocardial injury induced by AMI and the kinetics of 
associated biomarkers such as interleukin (IL-) 6,22 IL-8,23 C-reactive protein and fibrinogen 
are well known.24 Recently, underlying inflammatory pathways,25,26 interleukins associated 
with prognosis,27 as well as interleukins and their receptors as therapeutic targets have been 
explored in greater depth.28 However, the utility of inflammatory biomarkers in clinical 
practice remains largely uncertain. 
 
2.1.3 Current treatment strategies in ACS 
Modern evidence-based ACS management consists of early reperfusion therapy and 
revascularization, medical strategies with a combination of multiple drugs targeting platelet 
function and modifiable risk factors, and in certain cases with severe left ventricular 
dysfunction, device therapy such as cardiac resynchronization and implantable cardioverter 
defibrillators.7,8  
However, strategies for supportive care to relieve pain, breathlessness and anxiety are to date 
still based on expert opinion only.8 
 
2.1.4 Prevalence and prognosis 
In Sweden during 2014, 27,000 individuals developed an AMI, of whom 22,500 were 
hospitalized. Thirty-day mortality after MI was 26% for all patients and 11% for those 
hospitalized. The number with MI as an underlying or contributory cause of death was 7,000 
individuals29. The number of patients initially treated for symptoms suggestive of AMI is 
unknown, but chest pain remains the most common reason for visits to the emergency 
department, amounting to about 20% of all visits.30  
Although cardiovascular mortality has declined substantially in recent decades,31 coronary 
artery disease remains the leading cause of death both in Sweden32 and worldwide.1  
Introduction 
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2.2 OXYGEN THERAPY IN SUSPECTED ACUTE MYOCARDIAL INFARCTION 
  
2.2.1 History and rationale 
Oxygen as a medicinal substance was discovered independently by Scheele and Priestley 
1771-1775 and was henceforth the agent ubiquitous in modern medicine.33 Commercial 
oxygen became available surprisingly quickly and was used for all kinds of dubious purposes. 
A more scientific use of the drug became more common in the late eighteenth century with 
case reports on patients with pneumonia and tuberculosis. Steele was the first to describe the 
use of oxygen to relieve angina pectoris in 1900.6  
The rationale behind the widespread use of oxygen in patients with suspected AMI is based 
on the belief that inhaled oxygen therapy improves oxygen delivery to the diseased heart 
muscle, leading to reduced myocardial injury which thereby diminishes the risk for 
complications such as heart failure and arrhythmias.  
 
2.2.2 Physiological background and definitions 
Human life and most physiological processes depend on a continuous supply of oxygen to 
sustain cell function.34,35 Hypoxemia – low oxygen content caused by reduced oxygen 
delivery and/or failure of cellular use of oxygen – leads to organ dysfunction, cell and tissue 
damage, and ultimately death. To prevent these deleterious effects of hypoxemia is an 
essential aim of medical therapy.  
In contrast to hypoxemia, which is a common situation in disease or even physiologically at 
high altitudes, hyperoxemia - above-normal oxygen levels in the blood - is a man-made 
phenomenon which humans by nature are not equipped to handle. Hence, the body only 
detects unnatural high levels of oxygen by indirect factors in response to the stress of high 
oxygen tension.36 Clinically, the risk of inadvertent hyperoxemia is high because the standard 
monitoring is done non-invasively by pulse oximetry to avoid hypoxemia but does not allow 
assessment of above-normal levels. Hyperoxemia is feared to cause detrimental 
cardiocirculatory and metabolic effects (described in detail in 2.4).  
In the human body, oxygen is mainly bound to hemoglobin, a protein in the red blood cells. 
The relationship between the partial pressure of oxygen and the saturation of hemoglobin in 
the bloodstream is shown in the oxygen-hemoglobin dissociation curve. At levels above 6 
kPa, the standard dissociation curve is relatively flat, and the total oxygen content of the red 
blood cells does not change significantly despite large amounts of oxygen given (figure 1).37  
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Figure 1: Oxygen-hemoglobin dissociation curve adapted with DETO2X inclusion level of 
≥90% of blood oxygen saturation 
 
 
 
 
 
Table 1: Definitions 
 
Term Definition 
SaO2 Oxygen content in an arterial blood gas 
SpO2 Peripheral oxygen saturation (measured by pulse oximetry). An 
estimate of arterial oxygen saturation that refers to the amount of 
oxygenated hemoglobin in the blood 
PaO2 Partial pressure of oxygen 
FiO2 Fraction of inspired oxygen, meaning the amount of oxygen a patient 
breathes in (21% = room air, 30-40% = 6 L/min by open face mask) 
Hypoxemia Lack of oxygen at the level of the organ, tissue, or compartment. Refers 
to levels <85-90% or PaO2 <60 mmHg 
Hyperoxia High oxygen content (either excess O2 or higher than normal 
physiological pO2) 
Hyperoxemia Supranormal oxygen tension in the blood 
ROS Reactive oxygen species; chemically reactive molecules containing 
oxygen, such as superoxide, peroxide, hydroxyl and peroxyl radicals 
which are generated by enzymatic and non-enzymatic catalysis 
Modified with permission from Sepehrvand and Ezekowitz38 
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2.2.3 Experimental data supporting the use of oxygen in AMI 
In two studies on anesthetized dogs, inhalation of 40-100% oxygen after coronary artery 
occlusion reduced myocardial infarct size and improved left ventricular ejection fraction as 
compared to room air.39,40 In a small study in humans, 17 patients with anterior AMI received 
100% oxygen and a reduction in ST-segment elevation was seen on precordial ECG-
mapping.41  
Inspired by the hypothesis that a higher arterial oxygen tension reduces myocardial injury, 
other modalities have been evaluated. In a multicenter trial, 112 patients with STEMI were 
randomized to either hyperbaric oxygen or routine oxygen therapy during thrombolysis for 
anterior STEMI.42 No significant improvement was found with this technique. Another 
randomized multicenter trial used an even more advanced approach. A total of 269 STEMI 
patients were randomly assigned to either intracoronary hyperoxemic reperfusion after PCI of 
the diseased vessel or normoxemic reperfusion. At 30 days, there was no significant 
difference between the groups concerning infarct size, ST-segment resolution or wall motion 
score index. Later, a post-hoc analysis on a subgroup of patients (N=98) with anterior 
infarctions and early reperfusion proposed a benefit of hyperoxemic reperfusion on cardiac 
function.43 Based on the latter findings, a follow-up RCT directed at this group of patients 
was performed in 269 patients. Here, the investigators reported a significant reduction in 
infarct size with non-inferior rates of major adverse cardiovascular events at 30 days.44   
However, a meta-analysis performed in 2009 that pooled all available data on hyperoxic 
myocardial reperfusion therapy could not confirm positive findings.45 On the contrary it 
showed a significant decrease in coronary blood flow, an increase in coronary vascular 
resistance, and a significant reduction in myocardial oxygen consumption, suggesting 
possible harmful effects of hyperoxemic oxygen therapy.  
Using an updated device, a new RRCT is currently enrolling patients to confirm the safety 
and effectiveness of hyperoxemic reperfusion therapy (Evaluation of Intracoronary 
Hyperoxemic Oxygen Therapy in Anterior Acute Myocardial Infarction Patients, 
NCT02603835). 
 
2.2.4 Experimental data against the use of oxygen in AMI 
Already as early as 1950 Russek and colleagues warned that the indiscriminate use of oxygen 
in normooxic ACS patients might be harmful.46 Even more so today, concerns have been 
raised that the omnipresent, routine use of oxygen might be based more on tradition than 
solid scientific evidence.11,47-50 Proclaimed harmful effects are mainly based on two 
phenomena:  
1) hyperoxemia-induced vasoconstriction in the cardiac vasculature;51 and  
2) increased endothelial production of reactive oxygen species (ROS).38,52,53  
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Hyperoxemia-induced vasoconstriction deteriorates cardio-circulatory parameters such as 
coronary and systemic oxygen delivery,54 left ventricular perfusion,54 coronary blood flow,55-
58 it leads to increase in coronary vascular resistance55,56,59-61 and ultimately to reduced 
cardiac output.54,57,59,60,62 Several underlying mechanisms  have been proposed: closure of 
K+ATP channels,
63 activation of the angiotensin I - angiotensin II - endothelin 1 axis,64 direct 
effects on L-type Ca2+ channels,65 and increased production of 20-HETE,66 a powerful 
vasoconstrictor. 
Furthermore, the generation of ROS leading to a reduced bioavailability of nitric oxide seems 
to be of great importance in the pathophysiology of vasoconstriction.53,61,67 High levels of 
ROS overpower the body’s antioxidant capacity, resulting in a cascade of adverse reactions 
such as: increased oxidative stress, activation of apoptosis, creation of a prothrombotic 
environment, intracellular calcium overload and aggravated inflammatory response, all of 
which contributes to tissue damage, which determines the final infarct size.68,69  
Some experimental studies propose increased systemic inflammation to be the leading 
mechanism behind hyperoxemia-related observations70-72 whereas other studies could not 
support these findings.73,74 To the best of our knowledge, the effect of hyperoxemia on the 
inflammatory response to AMI has not been previously studied in humans. 
Independently, ROS activation can directly induce electro-physiological changes which can 
heighten the risk of malignant arrhythmias.75 Clinically, vasoconstriction mediated by oxygen 
therapy may result in underestimation of vessel size during PCI, potentially increasing the 
risk of subsequent stent thrombosis, a powerful predictor of adverse events.76,77 
 
Figure 2: Schematic illustration of proposed hyperoxemia-induced adverse effects in AMI 
 
 
Modified with permission from Shuvy et. al.11 
Introduction 
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2.2.5 Clinical trial data 
An updated 2016 report from the COCHRANE library reviewed the data available from 
randomized controlled trials (RCT) on oxygen therapy for AMI.47 Five studies were included: 
Rawles and Kenmure from 1976,78 Wilson and Channer from 1995,79 Ukholkina et. al. from 
2005,80 Ranchord from 201281 and Stub from 201582 adding up to a total of 1,173 patients in 
the meta-analysis. No significant difference was found between supplemental oxygen and 
ambient air concerning all-cause death or pain relief.  
In summary, the authors conclude: “There is no evidence from randomized controlled trials 
to support the routine use of inhaled oxygen in people with AMI, and we cannot rule out a 
harmful effect. Given the uncertainty surrounding the effect of oxygen therapy on all-cause 
mortality and on other outcomes critical for clinical decision, well-conducted, high quality 
randomized controlled trials are urgently required to inform guidelines in order to give 
definitive recommendations about the routine use of oxygen in AMI” (cited with permission 
from the authors). 
Scrutinizing the most recent studies in greater detail, the Australian Air Versus Oxygen in 
myocarDial infarction (AVOID) trial included 441 STEMI patients who were randomized to 
receive oxygen (8 L/min) or no oxygen and followed for 6 months. Mean peak creatine 
kinase was elevated in the patient on oxygen, whereas no differences in mean peak troponin I 
were detected. Follow-up data indicated an increased risk of recurrent myocardial infarction 
and a larger infarct size on cardiac magnetic resonance imaging (CMR) at 6 months in the 
oxygen treated group.82,83 In a post hoc analysis, high oxygen exposure was associated with 
clinically significant increase in CK and troponin I.84 However, the validity of these 
conclusions has been questioned.85 The Swedish Supplemental Oxygen in Catheterized 
Coronary Emergency Reperfusion (SOCCER) trial included 95 STEMI patients randomized 
to oxygen (10 L/min) or no oxygen and assessed myocardial damage by modern CMR 
parameters. No significant differences in myocardial salvage index, myocardium at risk or 
infarct size was found.86,87 
Both trials were underpowered to assess effects on cardiovascular morbidity and mortality, so 
the conclusion from the Cochrane report persisted: A definite RCT was still urgently 
required. 
 
Aims 
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3 AIMS 
 
The overall aim of the DETO2X trial series was to illuminate the role of routine oxygen 
therapy in AMI patients by building a trial concept and nationwide alliance to evaluate hard 
clinical endpoints in a large, randomized, registry-based clinical trial and assess possible 
underlying pathophysiological mechanisms in a biomarker substudy.  
 
3.1 SPECIFIC AIMS 
 
 To develop a study concept that enables a nationwide clinical trial using established 
AMI treatment routines without influences from the medical industry; to implement a 
study organization and logistics to perform the trial; to test the concept concerning 
logistics, safety and feasibility in a three months’ pilot study at Södersjukhuset. 
 
 To study the long-term effect of oxygen therapy on mortality in patients with 
suspected AMI in a prospective, registry-based randomized clinical trial (RRCT) 
across Sweden based on the SWEDEHEART registry.  
 
 To assess, in a substudy from the DETO2X trial, if supplemental oxygen given in the 
clinical ACS setting increases the release of inflammation-related biomarkers.  
 
 
Methods 
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4 METHODS 
 
4.1 ETHICAL CONSIDERATIONS AND RISK-BENEFIT ANALYSIS 
The studies were conducted in accordance with the Declaration of Helsinki88 and Good 
Clinical Practice Guidelines89 in the latest version. Approval was given by the ethics 
committee as well as from the Swedish Medical Products Agency. 
Apart from the assignment to the study group, patients enrolled in the DETO2X-AMI study 
followed routine AMI treatment. Oxygen therapy at a flow rate of 6 L/min for 6-12 hours 
given by open face mask is commonly used in clinical practice and is considered safe and 
well-tolerated by patients. The study protocol ensured that if hypoxemia developed in either 
group, supplemental oxygen was provided immediately.  
The possible benefit of the trial was to provide new evidence of the effects of oxygen therapy 
on cardiovascular morbidity and mortality in patients with suspected AMI. If these patients 
would either be put at risk of harm or not be found to gain from this therapy, it should 
consequently be removed from the treatment guidelines. 
Overall, we considered the risk of participation in the present trial to be very low and greatly 
exceeded by possible benefits of gaining new knowledge. 
 
4.2 PATIENTS 
The DETO2X trial series was constituted of 129 patients in the pilot study (study I) recruited 
at Södersjukhuset, Stockholm; 6,629 patients in the main national multicenter trial (study II) 
enrolled at 35 sites across Sweden, and 144 patients in the biomarker substudy (study III) 
recruited at Södersjukhuset, Stockholm and at Linköping University hospital, Linköping. 
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4.3 PILOT STUDY (STUDY I) 
 
4.3.1 Trial organization, logistics, communication and education 
From the start the DETO2X-AMI trial was planned as a two-center RCT at Södersjukhuset in 
Stockholm and at Sahlgrenska University Hospital in Gothenburg. When the study board 
realized that the necessary sample size could not be achieved this way, SWEDEHEART 
(Swedish Web-system for Enhancement and Development of Evidence-based care in Heart 
disease Evaluated According to Recommended Therapies), a national quality of care registry 
for patients with ischemic heart disease, was approached for cooperation, suggesting a 
nationwide RRCT design (details below). SWEDEHEARTs leadership was interested but 
wished for a pilot study to establish a model trial organization and test logistics and 
communication between participating units. Södersjukhuset in Stockholm was chosen as the 
primary site.  
In patients with suspected AMI, oxygen therapy is usually initiated at first medical contact 
when the patient is treated by ambulance staff or at the emergency department (ED). 
According to established clinical practice, these units immediately contact the coronary care 
unit (CCU) to discuss treatment options such as acute coronary angiography or medication. 
To optimize the cooperation and logistics between these units – usually belonging to different 
departments or even care providers – was of utmost importance for the success of the trial. 
Therefore, the local study organization was constituted of a local primary investigator (PI) 
who led a group of designated representatives from the ambulance service, ED, cath lab and 
the CCU. Several “DETO2X ambassadors” promoted trial procedures under their guidance. 
 
Figure 3: Schematic illustration of model trial organization  
 
 
Site PI
ED           
representative
DETO2X ambassadors 
Information, education, 
assistance of staff
CCU/ward        
cath lab
representative
DETO2X ambassadors 
Information, education, 
assistance of staff
Ambulance 
representative
DETO2X ambassadors
Information, online education, 
assistance of staff
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To simplify logistics, communication and education, a webpage (www.deto2x.se) was 
launched to spread information, updates and news, supply forms and education material, and 
to enable networking and facilitate cooperation. 
 
Figure 4: Schematic illustration of logistics, communications and education 
 
 
 
4.3.2 Patient recruitment and flow chart 
Eligible patients presenting with symptoms indicative of ACS (chest pain and/or typical 
dyspnea), SpO2 ≥90%, age ≥ 30 years, ECG changes indicating ischemia (ambulance/ED) 
and/or elevated cardiac troponin levels (ED) were asked to participate in the trial by 
ambulance staff or ED personnel. Patients were excluded if they were not willing to 
participate, were unable to provide informed consent, had on-going oxygen therapy or had 
experienced cardiac arrest before inclusion. After giving oral consent, patients were 
randomized assisted by CCU staff to receive either 6 L/min of oxygen by open face mask for 
12 hours or ambient air. Other therapies were left to the discretion of the treating physician. 
Oxygen saturation was documented at the beginning and at the end of the study period. If 
hypoxemia developed, patients could receive supplemental oxygen outside the trial protocol 
which was reported separately. To minimize unintentional crossover, stickers and patient 
bracelets were used that indicated the randomized group. Patients received comprehensive 
written study information directly after being admitted to a ward and were requested to 
confirm informed consent by signature. Data regarding baseline characteristics, presentation, 
in-hospital course and treatments were obtained from the SWEDEHEART registry. 
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Figure 5: Flow chart study I 
 
 
* Inclusion criteria: symptoms suggestive of AMI within 6 hours, SpO2 ≥ 90%, ≥ 30 years, 
ECG changes indicating ischemia and/or elevated troponin levels. 
* Exclusion criteria: unwillingness to participate, inability to provide informed consent, 
continuous oxygen treatment or cardiac arrest prior to enrollment. 
 
4.4 REGISTRY-BASED RANDOMIZED CLINICAL TRIAL (STUDY II) 
 
4.4.1 SWEDEHEART and the RRCT trial concept 
After successfully completing the pilot study, the DETO2X-AMI trial was launched as a 
multicenter, prospective, registry-based, randomized clinical trial (RRCT). This trial concept 
was established in the Thrombus Aspiration in ST-Elevation myocardial infarction in 
Scandinavia (TASTE) trial.90,91 This trial design utilizes the setting in Sweden where most 
patients with coronary artery disease are recorded in the SWEDEHEART registry, a national 
quality of care registry which includes RIKS-HIA (national registry of acute coronary care), 
SCAAR (national registry of angiography and angioplasty), the Swedish heart surgery 
registry and SEPHIA (national registry of secondary prevention).92  
The registry is web-based with all data documented online directly by the user. The platform 
is linked to the Swedish National Population Registry for direct access to personal data and 
vital statistics.93 For hospitalized patients with symptoms suggestive of ACS, data are 
gathered prospectively for 106 variables and include: patient demographics, admission 
logistics, risk factors, past medical history, medical treatment prior to admission, 
electrocardiographic changes, biochemical markers, other clinical features and investigations, 
medical treatment in hospital, interventions, hospital outcome, discharge diagnoses and 
discharge medications.  
Eligible* patient: 
After oral informed consent
1:1 randomization
in ambulance or ED 
Oxygen
6 l/min for 12 hours
via open face mask
Ambient air 
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SWEDEHEART provides manuals, education and technical advice, including a telephone 
help desk for all users. To ensure the correctness of the data, designated monitors visit the 
hospitals regularly. The agreement between key variables in the registry and medical records 
has repeatedly been 95-96%.92 
In the DETO2X-AMI trial, randomization was performed by means of an online 
randomization module imbedded in SWEDEHEART. Inclusion and exclusion criteria needed 
to be confirmed before the patient was assigned to one of the treatment arms. At the same 
time, enrolled patients were automatically recorded in the SWEDEHEART registry, enabling 
direct access to relevant clinical and outcome data. No further documentation was needed.  
Mortality data after discharge was obtained by merging with the Swedish population registry, 
which includes information on the vital statistics of all Swedish citizens. Due to the unique 
personal identification number of all Swedish citizens, virtually complete follow-up was 
achieved as deficiencies in reporting deaths and emigration is assumed to be less than 0.5 
percent.93  
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4.4.2 National trial organization 
To coordinate participating sites and optimize cooperation and logistics, a stringent national 
trial organization was implemented. The executive group met regularly for trial management 
and carried out all decisions and trial procedures with assistance of the steering group. For the 
ambulance service, two national coordinators facilitated contacts and assisted if needed. The 
local operative units were implemented as tested in the pilot study and were continuously 
aided by SWEDEHEART staff. The academic research organization with trial management, 
monitoring and statistical assistance was provided by the Uppsala Clinical Research Center 
(UCR), Uppsala, Sweden.  
 
Figure 6: Schematic illustration of national trial organization 
 
 
  
Executive group 
Designated senior researchers,   
statistician and clinicians
Steering group
Representatives from all regions 
in Sweden
Site Operative Unit  
as described in pilot study
Ambulance
National and local 
coordinators
Hospital 
as described in pilot 
study
UCR                 
Project managment 
Statistics
SWEDEHEART 
Monitoring      
National coordinator
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4.4.3 Flow chart (enrollment, allocation, follow-up, analysis) 
 
 
  Patient contact with ambulance 
service or emergency department 
Unrestricted online 1:1 randomization on CCU using SWEDEHEART  
Oxygen  
Delivered by open face mask 
at 6 L/min continuously for 6-
12 hours 
Standard ACS treatment 
Ambient air  
No oxygen given if O2 
saturation ≥ 90%. 
Standard ACS treatment 
Primary endpoint: 1-year all-cause mortality                       
Additional secondary endpoints 
Follow-up based on Swedish Population Registry and SWEDEHEART  
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4.5 SUBSTUDY ASSESSING EFFECTS OF SUPPLEMENTAL OXYGEN ON 
THE SYSTEMIC INFLAMMATORY RESPONSE TO AMI (STUDY III) 
The DETermination of the role of OXygen in acute myocardial infarction by biomarkers 
(DETO2X-biomarkers) was a pre-specified multicenter substudy to the DETO2X-AMI trial 
with Södersjukhuset and Linköping University Hospital as participating units.  
Patients recruited in the main trial were asked to participate in the DETO2X-biomarkers 
substudy whenever qualified research staff was available for lab assistance. Baseline blood 
samples where obtained as soon as possible after randomization, and a follow-up blood 
sample was secured 5-7 hours later. Apart from that, patients followed the regular DETO2X-
AMI study protocol as well as standard care but were registered on a separate CRF.  
The primary outcome was the effect of oxygen on systemic inflammation. A multiplex panel 
with 92 markers was analyzed by the Clinical Biomarkers facility, Science for Life 
Laboratory, Uppsala University, Uppsala. Personnel conducting the analysis were blinded to 
the allocated therapy. Analyses were carried out with a high-throughput technique on the 
Olink Proseek® Multiplex Inflammation I 96*96 kit (Olink Bioscience AB, Uppsala, 
Sweden), which measures 92 selected inflammatory disease related proteins simultaneously 
in plasma samples. A proximity extension assay (PEA) technology was used, where 92 
oligonucleotide-labeled antibody probe pairs can bind to their respective targets present in the 
sample.94,95 The kit has been shown to have high reproducibility and repeatability.95 The 
platform supplies normalized protein expression (NPX) data where a high DNA amplicon 
value equals a high protein concentration but does not enable an absolute quantification.  
The protein markers included on the Inflammation I 96*96 assay are given in the supplement 
to study III.         
To allow adjustment for the systemic inflammation caused by the size of the myocardial 
injury, plasma levels of highly sensitive cardiac troponin T were analyzed at the same time 
points using an electrochemiluminescence immunoassay (Troponin T hs STAT, Roche 
Diagnostics, Mannheim, Germany) on the Elecsys 2010 immunoassay analyzer (Roche 
Diagnostics). 
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4.6 STATISTICAL CONSIDERATIONS 
 
4.6.1 General 
Baseline characteristics are tabulated by randomized treatment group. Categorical data are 
depicted as total number and percentage. Numerical data is described using number of 
patients with data and median with interquartile range or arithmetic mean with standard 
deviations where applicable. Statistical testing comparing the randomized treatment groups 
was performed using chi-square tests or Fisher’s exact test for categorical variables and 
Wilcoxon's signed-rank test for non-parametric numerical data. The results are presented as 
p-values if statistical testing was performed. A p-value < 0.05 was considered statistically 
significant. 
Because the groups are randomized, all perceived differences are expected to be due to 
chance. 
 
4.6.2 Study II 
There are basically three methods of analysis available in clinical research when comparing 
two therapies: 1) superiority (A is better than B or B is better than A); 2) equivalence (A is as 
good as B); 3) non-inferiority (A is not worse than B).  
Equivalence and non-inferiority trials depend on certain assumptions. The basic demand is 
that superior efficacy of the standard treatment over placebo has been conclusively shown for 
a certain indication in earlier trials.96 As described in 2.5, no high quality clinical data on 
oxygen versus ambient air was available, resulting in a superiority efficacy analysis being the 
only available option for the DETO2X-AMI trial. Furthermore, choosing a two-tailed 
superiority design enabled both potential benefit and harm to be shown in a two-sided 
analysis.  
The primary endpoint was death of all causes within one year. The time-to-event analysis of 
all-cause death within 365 days after randomization is presented as Kaplan–Meier curves. 
Hazard ratios were calculated using Cox proportional-hazards model, with adjustment for age 
in years (as a linear covariate on the log-hazard scale) and sex.97 Estimates of differences 
between the study groups are presented with two-tailed 95% confidence intervals and 
associated p-values. A two-tailed p-value < 0.05 was considered statistically significant. 
Subgroup analyses were performed with the use of proportional-hazards models with 
adjustment for age and sex and formal tests for interaction. 
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4.6.3 Study III  
The primary endpoint was the effect of oxygen on the systemic inflammatory response to 
AMI assessed by 92 inflammatory biomarkers provided as normalized protein expression 
(NPX) data. The NPX are on log2 scale. Biomarkers with values below the lower limit of 
detection (LLOD) were set at LLOD/2. Twenty-seven proteins with less than 85% valid 
measurements of that protein were excluded from further analysis. Thus, 65 proteins were 
analyzed (complete list in Supplementary Table). 
Linear regression was used for the primary endpoint. The treatment effect on each biomarker 
(at 5-7 hours post randomization) was estimated in a model with the baseline value of each 
biomarker as covariate (i.e. adjusting for the baseline value). Results are in table format with 
beta estimate, 95% confidence interval and p-value and are also shown as a forest plot. 
Descriptive values shown are median with interquartile range (IQR). The statistical test for 
the comparison between treatment and baseline levels, irrespective of randomized group, was 
a paired t-test.  
Two thresholds of significance were used: A nominal significance level of p <0.05 and a 
threshold calculated for the primary endpoint using permutation tests. The permutation 
procedure gave the result that p <0.001 was needed for significance at the 5% level. 
 
4.6.4 Power calculations 
Being a pilot study for feasibility, no power calculations were performed for study I. 
For study II, sample size calculations were based on observational clinical trials98,99 and 
historical data from SWEDEHEART between 2005-2010. The one-year total mortality 
among patients with confirmed myocardial infarction was estimated to be around 12%. A 
clinically relevant effect of supplemental oxygen was defined as a 20% relative risk 
reduction. We expected that before 2010 the great majority of patients were according to 
guidelines generally treated with oxygen. Thus, assuming a significant benefit of oxygen 
treatment, the mortality rate in the ambient-air group would come up to 14.4%. With the chi-
square test, to be able to reject the null hypothesis at a significance level of 0.05 (two-tailed) 
with a power of 0.90, a total of 2,856 patients per group were needed. To control for patients 
crossing over or not completing the trial, the planned sample size was increased to 3,300 
patients per group, which resulted in a total of 6,600 patients. 
Sample size calculations for study III were based on previous published data.100 To be able to 
reject the null hypothesis at a significance level of 0.05, and with a power of 0.80, an 
estimated number of 140 patients (70 O2, 70 ambient air) would suffice to show significant 
differences in biomarkers levels.  
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5 RESULTS 
 
5.1 STUDY I 
We performed a single center pilot study at Södersjukhuset, Stockholm, between October 
2012 and January 2013. A total of 129 normooxic patients were enrolled by the ambulance 
service or at the emergency department and randomized in a 1:1 ratio to either oxygen at 6 
L/min for 12 hours delivered via open face mask or ambient air.  
Except for being younger, baseline characteristics were similar to those seen in the overall 
SWEDEHEART population (table 2). A total of 81 (63%) patients were diagnosed with AMI 
(53% NSTEMI and 47% STEMI). Of those that remained, 32 (25%) patients were diagnosed 
with other acute cardiac conditions such as angina pectoris, myocarditis, heart failure, 
Takotsubo cardiomyopathy, or valvular disease. Sixteen (12%) patients received unspecified 
chest pain as primary diagnosis. No substantial logistical or medical problems occurred. 
Oxygen treatment for 12 hours was well accepted. Crossover from ambient air to oxygen 
occurred in two patients who developed hypoxemia due to pulmonary edema. There was no 
crossover from oxygen to ambient air. At 30 days, there were 3 (4.6%) deaths in the ambient-
air group and no deaths in the oxygen group (p=0.12, Fisher´s Exact test). 
 
Figure 8: Schematic illustration of patient distribution and final diagnoses 
 
⃰ According to the universal definition of myocardial infarction, 3rd edition101 
 
  
Eligible patients with suspected AMI
Non-AMI Type I ⃰
37%
Unspecified 
chest pain / 
other diagnosis 
Other cardiac 
diagnosis
AMI Type II ⃰
AMI Type I ⃰
63%
NSTEMI     
53%
STEMI 
47%
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Table 2: Baseline characteristics and final diagnoses in the DETO2X-AMI pilot study 
  
All 
(N=129) 
 
 
Oxygen 
(N=65) 
 
Ambient air 
(N=64) 
 
Demographics – no. (%)    
Age, median (IQR) 68 (58-78) 69 (58-78) 65 (58-76) 
Men 87 (67) 40 (62) 47 (73) 
Risk factors – no. (%)    
Current smoking 26 (20) 13 (20) 13 (20) 
Diabetes Mellitus 21 (16) 16 (25) 5 (8) 
Hypertension 51 (40) 27 (42) 24 (38) 
Previous CV disease – no. (%)    
Myocardial infarction 26 (20) 11 (17) 15 (23) 
Percutaneous coronary intervention 25 (19) 9 (14) 16 (25) 
Coronary artery by-pass graft 4 (3) 2 (3) 2 (3) 
Stroke 3 (2) 1 (2) 2 (3) 
Medication on admission – no. (%)    
Aspirin 39 (30) 20 (31) 19 (30) 
Clopidogrel 2 (1.6) 1 (1.5) 1 (1.6) 
Beta-blocker 41 (32) 23 (35) 18 (28) 
Statin 34 (26) 18 (28) 16 (25) 
ACE-inhibitors or ATII-blockers 37 (29) 21 (32) 16 (25) 
Presentation – no. (%)    
Ambulance transportation 82 (64) 40 (62) 42 (66) 
Systolic blood pressure – mmHg  150 (135-170) 150 (133-168) 150 (136-191) 
Heart rate - beats/min (IQR) 80 (67-93) 81 (67-92) 80 (67-93) 
Electrocardiography – no. (%)    
ST-elevation 48 (37) 21 (32) 27 (42) 
ST-depression 28 (22) 15 (23) 13 (20) 
T-wave inversion 18 (14) 10 (15) 8 (13) 
Normal or other 35 (27) 19 (29) 16 (25) 
Final diagnosis – no. (%)    
Myocardial infarction 81 (63) 42 (65) 39 (61) 
Unstable or stable angina 17 (13) 6 (9) 11 (17) 
Other heart disease 15 (12) 9 (14) 6 (9) 
Unknown/other non-cardiac cause 16 (12) 8 (12) 8 (13) 
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5.2 STUDY II 
Trial Population 
Of the 69 hospitals in Sweden with acute cardiac care facilities, 35 participated in the trial. 
Between April 13, 2013, and December 30, 2015, a total of 6,629 patients with suspected 
myocardial infarction were enrolled and included in the intention-to-treat analysis (figure 9).  
 
Figure 9: Enrollment, randomization, and analysis 
 
Adapted with permission from NEJM102 
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The baseline characteristics and clinical presentation of all the patients, as well as the final 
diagnoses, were similar in both groups (table 3). 
 
Table 3: Baseline characteristics, clinical presentation, and discharge diagnoses  
  
Oxygen 
(N=3,311) 
 
 
Ambient air 
(N=3,318) 
 
Demographics – no. (%)   
Age – years, median (IQR) 68.0 (59.0-76.0) 68.0 (59.0-76.0) 
Male sex  2,264 (68.4) 2,342 (70.6) 
Risk factors – no. (%)   
Body-mass index 27.1±4.4 27.2±4.4 
Current smoking 704 (21.3) 721 (21.7) 
Hypertension 1,575 (47.6) 1,559 (47.0) 
Diabetes mellitus 589 (17.8) 644 (19.4) 
Previous CV disease – no. (%)   
MI 682 (20.6) 667 (20.1) 
PCI 525 (15.9) 549 (16.5) 
CABG 208 (6.3) 206 (6.2) 
Causes of admission   
Chest pain 3,123 (94.3) 3,120 (94.0) 
Dyspnea 63 (1.9) 77 (2.3) 
Cardiac arrest 1 (0.0) 1 (0.0) 
Medication on admission – no. (%)   
Aspirin 904 (27.3) 961 (29.0) 
P2Y12 Receptor Inhibitors 177 (5.4) 173 (5.2) 
Beta-blockers 1,030 (31.1) 1,052 (31.7) 
Statins 884 (26.7) 895 (27.0) 
ACE-inhibitors or AT II-blocker 1,186 (35.8) 1,237 (37.3) 
Calcium-blockers 617 (18.6) 615 (18.5) 
Diuretics 543 (16.4) 525 (15.8) 
Presentation    
Time from symptom onset to randomization 
minutes, median (IQR) 
245.0  
(135.0-450.0) 
250 
(134.0-458.0) 
Ambulance transportation – no. (%) 2,215 (66.9) 2,218 (66.8) 
Systolic blood pressure – mmHg 150.3±27.8 148.7±28.0 
Heart rate – beats/min 78.6±19.3 78.1±19.5 
Oxygen saturation – %, median (IQR) 97 (95-98) 97 (95-98) 
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Oxygen 
(N=3,311) 
 
 
Ambient air 
(N=3,318) 
 
Discharge diagnosis   
MI (I.21+I.22)  
     STEMI 
2,485 (75.1) 
1,431 (43.2) 
2,525 (76.1) 
1,521 (45.8) 
Angina pectoris (code I.20) 189 (5.7) 185 (5.6) 
Other cardiac diagnosis 
     Atrial fibrillation (I.48) 
     Heart failure (I.50) 
     Cardiomyopathy (I.42) 
     Peri-myocarditis (I.30+I.40) 
     Pulmonary embolism (I.26) 
254 (7.7) 
52 (1.6) 
43 (1.3) 
48 (1.4) 
32 (1.0) 
7 (0.2) 
257 (7.7) 
44 (1.3) 
40 (1.2) 
46 (1.4) 
43 (1.3) 
9 (0.3) 
Pulmonary disease 
     Pneumonia (J.15+J.16) 
     COPD/asthma (J44+J45) 
17 (0.5) 
8 (0.2) 
2 (0.1) 
15 (0.5) 
7 (0.2) 
2 (0.1) 
Unspecified chest pain (R.07) 258 (7.8) 234 (7.1) 
Other non-CV diagnosis 
     Musculoskeletal pain (M.54+M.79) 
108 (3.3) 
7 (0.2) 
102 (3.1) 
14 (0.4) 
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Procedural Data 
The data on procedures, medication, and complications during the hospitalization period were 
similar in both groups except for the rate of patients developing hypoxemia, the oxygen 
saturation at the end of the treatment period and the use of iv inotropes (table 4). 
 
Table 4: Data on procedures, medication, and complications during hospitalization 
  
Oxygen 
(N=3,311) 
 
 
Ambient Air 
(N=3,318) 
 
p  
value 
Trial procedural data     
Duration of oxygen therapy 
hours, median (IQR) 
11.6  
(6.0-12.0) 
  
Received oxygen due to the 
development of hypoxemia 
62 (1.9) 254 (7.7) <0.001 
Oxygen saturation at end of treatment 
period – %, median (IQR)  
99 
(97-100) 
97  
(95-98) 
<0.001 
Procedures – no. (%)    
Coronary angiography 2,797 (84.5) 2,836 (85.5) 0.26 
PCI 2,183 (65.9) 2,246 (67.7) 0.13 
CABG 96 (2.9) 110 (3.3) 0.51 
Hospital stay – days, median  3.0 (0-68) 3.0 (0-95) 0.87 
Medication – no. (%)    
Iv diuretics 309 (9.3) 322 (9.7) 0.58 
Iv inotropes 46 (1.4) 70 (2.1) 0.02 
Iv nitroglycerin 252 (7.6) 221 (6.7) 0.14 
Aspirin 2,758 (83.3) 2,803 (84.5) 0.16 
P2Y12 Receptor Inhibitors 2,445 (73.8) 2,463 (74.2) 0.62 
Beta-blockers 2,702 (81.6) 2,752 (82.9) 0.13 
Statins 2,782 (84.0) 2,765 (83.3) 0.46 
ACE-inhibitors or AT II-blockers 2,586 (78.1) 2,557 (77.1) 0.32 
Calcium-blockers 519 (15.7) 547 (16.5) 0.36 
Diuretics 607 (18.3) 615 (18.5) 0.82 
Complications – no. (%)    
Reinfarction  17 (0.5) 15 (0.5) 0.72 
New-onset atrial fibrillation  94 (2.8) 103 (3.1) 0.53 
AV-block II or III 46 (1.4) 58 (1.7) 0.24 
Cardiogenic shock 32 (1.0) 37 (1.1) 0.54 
Cardiac arrest 79 (2.4) 63 (1.9) 0.17 
Death 53 (1.6) 44 (1.3) 0.35 
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Clinical Outcomes 
Follow-up data on mortality were obtained for all patients from the records of the Swedish 
National Population Registry. All other variables were obtained from SWEDEHEART (table 
5). 
The primary endpoint of death from any cause within 1 year after randomization occurred in 
5.0% of patients (166 of 3311) assigned to oxygen and in 5.1% of patients (168 of 3318) 
assigned to ambient air (hazard ratio, 0.97; 95% confidence interval, 0.79 to 1.21; P = 0.80) 
(figure 10).  
 
Figure 10: Kaplan-Meier curves for death from any cause 
Kaplan-Meier curves are shown for the cumulative probability of death from any cause up to 
365 days after randomization among patients assigned to oxygen or ambient air. The 
proportional-hazards assumption was subjected to post hoc testing by inserting a linear 
treatment–time interaction in the Cox proportional-hazards model, which did not noticeably 
improve the model fit (P = 0.61). The inset shows the same data on an expanded y-axis. 
 
 
Adapted with permission from NEJM102 
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The corresponding one-year mortality in the per-protocol population was 4.7% (141 of 3,014) 
and 5.1% (163 of 3,212), respectively (hazard ratio, 0.91; 95% confidence interval, 0.72 to 
1.14; P = 0.40). The findings for the primary endpoint were consistent across all prespecified 
subgroups. 
 
Figure 11: Prespecified subgroup analyses  
Hazard ratios (HR) are shown for the primary endpoint of mortality within 365 days after 
randomization in the intention-to-treat population, the per-protocol population and in 
subgroups of patients. ITT denotes intention-to-treat; PP per-protocol, AMI acute myocardial 
infarction, MI myocardial infarction, NSTEMI non-ST-segment elevation myocardial 
infarction, STEMI ST-segment elevation myocardial infarction, CKD chronic kidney disease, 
and PCI percutaneous coronary intervention. 
 
 
Adapted with permission from NEJM102 
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Secondary endpoints included rehospitalization with myocardial infarction within and the 
composite endpoint of death from any cause or rehospitalization with myocardial infarction at 
one year. No significant difference between the two groups was detected at 30 days regarding 
death, rehospitalization with myocardial infarction, or the composite of these two endpoints. 
Data on the highest measured level of highly sensitive cardiac troponin T during 
hospitalization were available for 3,976 of 5,010 patients (79.4%) with confirmed myocardial 
infarction, and this measure did not differ significantly between the study groups (table 5). 
 
Table 5: Endpoints during and after hospitalization 
 
 
Endpoint 
 
Oxygen 
(N=3311) 
 
 
Ambient Air 
(N=3318) 
 
Hazard Ratio  
(95% CI) 
 
P 
Value 
365 days – no. (%)     
All-cause death  166 (5.0) 168 (5.1) 0.97 (0.79-1.21) 0.80 
Rehospitalization with MI  126 (3.8) 111 (3.3) 1.13 (0.88-1.46) 0.33 
Composite of all-cause death 
or rehospitalization with MI 
275 (8.3) 264 (8.0) 1.03 (0.87-1.22) 
 
0.70 
30 days – no. (%)     
All-cause death  73 (2.2) 67 (2.0) 1.07 (0.77-1.50) 0.67 
Rehospitalization with MI  45 (1.4) 31 (0.9) 1.46 (0.92-2.31) 0.11 
Composite of all-cause death 
or rehospitalization with MI 
114 (3.4) 95 (2.9) 1.19 (0.91-1.56) 
 
0.21 
During hospital stay     
hs-troponin T – no. (%) 
median  
IQR 
1998 (80.4) 
946.5 
(243.0-2884.0) 
1978 (78.3) 
983.0 
(225.0-2931.0) 
  
0.97 
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Figure 12: Cumulative distribution of highly sensitive cardiac troponin T per treatment group 
For each troponin value displayed, the graph shows the proportion of patients below that cut-
point 
 
 
Adapted with permission from NEJM102 
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Outcomes among Patients Not Enrolled in the Trial 
During the trial period, a total of 22,872 patients with confirmed myocardial infarction were 
reported in the SWEDEHEART registry at participating sites, of whom 5,010 (21.9%) were 
enrolled in the DETO2X-AMI trial. The remaining 17,862 patients with confirmed 
myocardial infarction who did not undergo randomization were at higher risk for all the 
endpoints we considered, were more often admitted with dyspnea and after cardiac arrest 
(table 6), and had considerably worse outcomes than those with confirmed myocardial 
infarction who were enrolled in the trial (table 7). Patients with suspected but not confirmed 
myocardial infarction who were not enrolled in the trial are not recorded in the 
SWEDEHEART registry, and, therefore, data for such patients were not available for 
comparison. 
 
Table 6: Baseline characteristics, clinical presentation, and final diagnoses in patients with 
AMI enrolled and not enrolled in the DETO2X-AMI trial at participating sites during the trial 
period 
 
  
Enrolled in 
DETO2X-AMI  
(N=5,010) 
 
 
Not enrolled 
in the trial 
 (N=17,862) 
 
P 
value 
Demographics – no. (%)    
Age – years, median (IQR) 68.0 (60.0-76.0) 72.0 (63.0-82.0) <0.001 
Risk factors – no. (%)    
Hypertension 2,358 (47.1) 9,410 (52.7) <0.001 
Diabetes mellitus 932 (18.6) 4,289 (24.0) <0.001 
Previous CV- disease – no. (%)    
AMI 895 (17.9) 4,667 (26.1) <0.001 
PCI 694 (13.9) 3,187 (17.8) <0.001 
Causes of admission – no. (%)    
Chest pain 4,807 (95.9) 14,011 (78.4) <0.001 
Dyspnea 73 (1.5) 1,574 (8.8) <0.001 
Cardiac arrest 1 (0.0) 445 (2.5) <0.001 
Final diagnoses – no. (%)    
MI (I.21+I.22)  
     STEMI 
5,010 (100) 
2,952 (58.9) 
17,862 (100) 
5,710 (32.0) 
 
<0.001 
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Table 7: Endpoints per treatment group and randomization status at 30 days and at 365 days 
after randomization in patients with AMI enrolled and not enrolled in the DETO2X-AMI trial 
at participating sites during the trial period 
  
 
Endpoint 
 
Enrolled in  
DETO2X-AMI 
(N=5010) 
 
 
Not enrolled 
in the trial 
(N=17,862) 
 
Hazard Ratio 
(95% CI) 
 
P 
value 
365 days – no. (%)     
All-cause death  255 (5.1) 2861 (16.0) 0.30  
(0.26-0.34) 
<0.001 
Rehospitalization with MI  185 (3.7) 989 (5.5) 0.61  
(0.52-0.72) 
<0.001 
Composite of  
all-cause death or 
rehospitalization with MI 
412 (8.2) 3597 (20.1) 0.38 
(0.34-0.42) 
<0.001 
30 days – no. (%)     
All-cause death  125 (2.5) 1415 (7.9) 0.31  
(0.26-0.37) 
<0.001 
Rehospitalization with MI  63 (1.3) 286 (1.6) 0.75  
(0.57-0.99) 
<0.001 
Composite of 
all-cause death or 
rehospitalization with MI 
181 (3.6) 1668 (9.3) 0.38  
(0.32-0.44) 
<0.001 
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5.3 STUDY III 
Between November 2014 and December 2015, 164 eligible patients were included. Twenty 
patients were excluded from the analysis (figure 13). Consequently, 144 remained for 
analysis. At the time of randomization, the median oxygen saturation was 97%. Seventy-six 
(53%) patients were allocated to oxygen and 68 (47%) patients were allocated to ambient air. 
The median duration of oxygen therapy was 11.6 hours, with a median oxygen saturation of 
99% in patients assigned to oxygen and 97% in patients assigned to ambient air at the end of 
the treatment period (p<0.001). Overall, 74 patients (51%) received the discharge diagnosis 
ST-segment elevation myocardial infarction (STEMI) whereas 70 patients received the 
discharge diagnosis non-STEMI (table 8). Seventy-six patients (53%) were randomized to 
oxygen therapy and 68 patients (47%) to ambient air (figure 13). 
 
Figure 13: Enrollment, randomization and analysis 
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There were no significant differences in baseline characteristics and clinical presentation 
between the oxygen group and the ambient-air group except for the oxygen saturation at the 
end of the treatment period (table 8). 
 
Table 8: Baseline characteristics, clinical presentation, study procedural data, and infarction 
type in the DETO2X-biomarker substudy 
  
Oxygen 
(N=76) 
 
 
Ambient air 
(N=68) 
Demographics – no. (%)   
Age – years, median (IQR) 68.0 (58.5-77.0) 67.0 (58.0-73.5) 
Male sex  57 (75.0) 54 (79.4) 
Risk factors – no. (%)   
Body-mass index‡ 27.6±4.5 27.0±4.3 
Current smoking 17 (22.4) 14 (20.6) 
Hypertension 41 (53.9) 30 (44.1) 
Diabetes mellitus 18 (23.7) 9 (13.2) 
Previous cardiovascular disease – no. (%)   
Myocardial infarction 11 (14.5) 10 (14.7) 
Percutaneous coronary intervention 8 (10.5) 7 (10.3) 
Coronary-artery bypass graft 4 (5.9) 7 (9.2) 
Medication on admission – no. (%)   
Aspirin 15 (19.7) 13 (19.1) 
P2Y12 receptor Inhibitors 3 (3.9) 2 (3.0) 
Beta-blockers 19 (25.0) 19 (27.9) 
Statins 21 (27.6) 16 (23.5) 
ACE-inhibitors or AT II receptor blockers 33 (43.4) 25 (36.8) 
Calcium-blocker 19 (25.0) 14 (20.6) 
Diuretics 7 (9.2) 10 (14.7) 
Presentation    
Ambulance transportation – no. (%) 58 (76.3) 46 (67.6) 
Systolic blood pressure – mmHg 152.4±30.6 151.7±29.2 
Heart rate – beats/min 74.7±15.8 79.0±17.5 
Oxygen saturation – %, median (IQR) 97 (95-98) 97 (96-98) 
Trial procedural data    
Duration of oxygen therapy – hours, median (IQR) 11.7 (6.9-12.0) - 
Oxygen saturation at end of treatment period  
%, median† (IQR)  
 
100 (99-100) 
 
97 (96-98 
Infarction type   
STEMI 51 (67.1) 46 (67.1) 
NSTEMI 25 (32.9) 22 (32.3) 
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Markers of myocardial injury and inflammation 
When analyzing the overall NPX levels of the inflammatory biomarkers, eight* increased 
whereas 13** decreased from baseline to 5-7 hours after randomization (Table 2). At 
baseline, the median level of cardiac troponin T was 52.9 ng/L in patients assigned to oxygen, 
and 63.3 ng/L in patients assigned to ambient air. After 5-7 hours, it increased to 1,436 ng/L 
and 1,574 ng/L, resulting in a median difference of 1,403 ng/L, and 1,238 ng/L in the two 
groups, respectively (p= 0.696).  
 
Table 9: Overall summary of biomarkers with significant change over study period 
 
Biomarker 
 
Baseline Treatment 
Paired 
difference 
Percent 
change 
P value 
IL-6* 
2.0 
[1.6, 2.7] 
3.2  
[2.5, 3.8] 
1.1  
[0.4, 1.9] 
114 
[34, 265] 7.73e-24 
ST1A1* 
2.2  
[1.6, 3.3] 
3.1  
[2.0, 4.1] 
0.8 
[-0.3, 1.5] 
74  
[-17, 178] 3.64e-08 
IL-8* 
5.6  
[5.3, 6.1] 
5.9  
[5.5, 6.5] 
0.3  
[-0.1, 0.8] 
26  
[-8, 74] 1.85e-06 
VEGF-A* 
9.5  
[9.2, 9.9] 
9.7  
[9.4, 10.0] 
0.2  
[0.0, 0.5] 
17 
[-2, 37] 4.62e-06 
CD40* 
9.7  
[9.4, 10.1] 
9.9  
[9.5, 10.3] 
0.2  
[-0.2, 0.6] 
16  
[-11, 47] 5.26e-05 
CCL23* 
10.0  
[9.6, 10.5] 
10.2  
[9.8, 10.6] 
0.2  
[-0.1, 0.5] 
15  
[-8, 37] 1.64e-04 
PD-L1* 
3.8  
[3.4, 4.1] 
3.9  
[3.5, 4.3] 
0.2  
[-0.2, 0.5] 
13  
[-13, 40] 7.70e-04 
CSF-1* 
7.3  
[7.1, 7.5] 
7.4  
[7.1, 7.6] 
0.1  
[-0.1, 0.4] 
10  
[-9, 28] 3.48e-04 
      
TRAIL** 
7.4  
[7.2, 7.7] 
7.3  
[7.0, 7.6] 
-0.1  
[-0.4, 0.1] 
-9  
[-24, 8] 1.66e-04 
CXCL11** 
10.8  
[10.2, 11.2] 
10.5  
[9.9, 11.0] 
-0.2  
[-0.5, 0.1] 
-10 
[-31, 8] 1.09e-06 
TRANCE** 
3.5  
[3.1, 4.0] 
3.3 
[2.9, 3.8] 
-0.2  
[-0.7, 0.3] 
-11 
[-40, 20] 7.15e-04 
CCL19** 
9.5 
[8.9, 10.2] 
9.3  
[8.7, 9.9] 
-0.3  
[-0.6, 0.1] 
-16  
[-34, 10] 5.58e-07 
Flt3L** 
8.2  
[7.9, 8.6] 
7.9  
[7.5, 8.4] 
-0.3  
[-0.6, 0.0] 
-17  
[-32, -2] 6.29e-13 
CXCL6** 
8.6  
[8.0, 9.1] 
8.4  
[7.8, 8.9] 
-0.3  
[-0.7, 0.2] 
-18  
[-38, 16.] 7.31e-05 
HGF** 
7.8  
[7.1, 11.4] 
7.3  
[6.9, 8.0] 
-0.3  
[-3.9, 0.3] 
-18 
[-93, 25] 1.10e-07 
CCL25** 
6.2  
[5.7, 6.7] 
5.9  
[5.5, 6.3] 
-0.3  
[-0.6, 0.0] 
-18  
[-34, 0] 1.41e-10 
CXCL10** 
9.7  
[8.9, 10.6] 
9.3  
[8.6, 10.0] 
-0.3  
[-1.0, 0.2] 
-20  
[-50, 12] 3.37e-06 
TWEAK** 
8.7  
[8.3, 11.6] 
8.2  
[8.0, 8.7] 
-0.4  
[-3.5, 0.2] 
-24  
[-91, 13] 6.62e-11 
CXCL9** 
8.1  
[7.0, 9.5] 
7.3  
[6.6, 8.1] 
-0.4  
[-1.8, 0.1] 
-25  
[-72, 6] 1.99e-10 
IL-10** 
2.7  
[1.9, 3.3] 
2.0  
[1.6, 2.4] 
-0.5  
[-1.3, 0.1] 
-30  
[-59, 4] 3.56e-10 
OSM** 
2.5 
[1.9, 3.3] 
1.9  
[1.4, 2.9] 
-0.6  
[-1.6, 0.3] 
-33  
[-67, 25] 1.47e-04 
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When oxygen therapy was compared with ambient air, no statistically significant difference 
was detected for any of the inflammatory markers regardless of level of significance. After 
inclusion of the relative increase in cardiac troponin T levels over time, age, and sex as 
potential confounders, there were still no significant differences in the inflammatory response 
to AMI between the two groups (Figure 14). 
 
Figure 14:  Forest plot of the adjusted treatment effects on the PEA biomarkers 
 
                                                                        Beta [95% CI]
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6 DISCUSSION 
 
6.1 MAJOR FINDINGS 
The design of the DETO2X-AMI-trial was found to be safe, robust and feasible. Based on the 
experience of the pilot study, we conducted a pragmatic, registry-based, randomized clinical 
trial evaluating supplemental oxygen versus ambient air in patients presenting with suspected 
myocardial infarction who were not hypoxemic at baseline. We found neither a beneficial 
effect of oxygen treatment nor indication of harm with respect to all-cause mortality, 
rehospitalization with AMI or the extent of myocardial injury. Furthermore, no impact on the 
early systemic inflammatory response to AMI was detected.  
Both beneficial and deleterious effects of oxygen therapy in AMI patients have been 
proposed (discussed in detail in chapter 2.2). The different results compared to our trial may 
have multiple reasons.  
Adverse effects have been shown in experimental studies and smaller clinical trials with high 
doses of up to 100% oxygen by closed face mask. A dose-dependent correlation between 
oxygen exposure and risk for hyperoxemia-related myocardial injury might be the underlying 
reason which has been postulated in experimental animal models70,103 and was also reported 
in a post-hoc analysis of a recent clinical study.84 Our trial used moderate oxygen doses by 
open face mask thereby avoiding excessive hyperoxemia. Furthermore, in experimental 
studies, hemodynamic, histologic or biochemical markers were analyzed immediately or 
within a short period of time in a small number of subjects.54-56 In contrast, our study had 
long median follow-up. Hemodynamic changes might be transient with limited sustained 
long-term risk.  
Positive effects were reported in smaller clinical trials evaluating surrogate endpoints, and in 
some, using a different approach.44,80,104 Our trial was assessing the routine use of 
supplemental oxygen in current clinical practice where hyperbaric or superoxygenated ways 
of oxygen delivery are still not established therapeutic choices. Generally, discrepancies 
between preclinical studies and smaller clinical trials with surrogate endpoints, and large 
clinical trials with hard outcomes are common and might explain the difference in our 
findings.  
 
6.2 THE USE OF OXYGEN IN SUSPECTED AMI - A RELEVANT QUESTION 
FOR THE CAREGIVER, THE HEALTH CARE SYSTEM OR US? 
In the background section of this thesis, I tried to build a scientific case arguing that the 
widespread use of oxygen in the absence of solid scientific evidence demanded a large, 
randomized trial clarifying this controversy. But is this quest also relevant for clinicians in 
Discussion 
   
DETO2X-AMI │ 40 
daily routine? Does it matter for health care systems in the larger perspective? And lastly, 
why did we attempt to resolve this issue and not wait for somebody else to do it for us? 
It is difficult to judge how many patients with suspected AMI are treated with oxygen per 
year in Sweden as this aspect is not routinely recorded. Around 20,000 patients annually 
receive the primary diagnosis AMI which is only one-fifth of the patients admitted to the ED 
with chest pain. If patients with dyspnea are included, the numbers increase even further. 
With this simple estimation, it becomes clear that health care professionals are regularly 
confronted with the decision of whether to use oxygen or not. On top of that, the belief in the 
power of the drug is still very strong. In a recent survey of health professionals assessing the 
reason for using oxygen in suspected AMI, 96% of the respondents generally used oxygen in 
these patients, 50% of whom did so believing it would reduce mortality.105 Some others argue 
that even if it might not do much good, it is at least harmless.106 This point of view has been 
argued fiercely,11,50,107 and today most experts seem to agree that oxygen is a potent 
vasoactive drug which should be used cautiously.   
Health care systems across the world battle with galloping costs. Concerning oxygen, costs 
are certainly not negligible. Basic calculations for the in-hospital costs of the drug alone come 
up to $10/day per patient,11 much more when considering pre-hospital care as well. If adding 
delivery and storage systems and staff the sum increases substantially to an estimated 
$100/day per patient,38 resulting in a significant financial burden. If the use of oxygen therapy 
was shown to be without effect or even harmful, costs could be reduced significantly.  
To perform a high quality RCT when trying to assess a relevant clinical problem is 
demanding for several reasons. Most importantly, it is expensive and difficult to organize 
because of the lack of funding and infrastructure from the industry. Furthermore, acceptance 
from the medical community or the public to challenge a common knowledge is problematic 
and others have found it difficult to perform such a trial.105 So why were we able or even 
obliged to do it? Simply because we could. The Ethical Review Board and the Medical 
Product Agency believed in the cause and gave us permission for the trial; we received 
unrestricted study grants from The Swedish Heart-Lung Foundation, the Swedish Research 
Council and the Swedish Foundation for Strategic Research for the execution of the study; 
the infrastructure and resources of the SWEDEHEART network permitted logistics and 
support; and most of all the enthusiasm and unwavering engagement of health care personnel 
throughout the country enabled us to complete this trial.     
 
6.3 RRCT - POSSIBILTIES AND LIMITATIONS OF A NEW CONCEPT 
The possible advantages and disadvantages of RRCTs have been discussed in detail 
recently.90,108-113 In short, the RRCT concept comes with many of the features for which 
regular RCTs became gold standard in clinical research; accounting for the effects of 
unmeasured confounders and selection bias by indication through randomization. 
Furthermore, some of the general drawbacks are omitted. A RRCT is not only much less 
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expensive to perform but also enrolls a broader patient population making the results more 
applicable to the underlying population than those from a regular RCT with narrow inclusion 
criteria and multiple exclusion criteria. In the present study, using the RRCT concept enabled 
us to recruit 6,629 patients from an all-comer, real-life population from all over Sweden in 
less than 3 years. Where regular large RCTs recruitment per site is generally low (estimated 
around 1 patient per month)114 and challenging,115 we achieved an average inclusion rate of 
5.8 patients per month per site optimizing commitment and compliance of participating units. 
Lastly, using the well-established registry infrastructure of SWEDEHEART, we could reduce 
costs substantially (roughly 5mkr, a small fraction of the cost of a RCT of similar size)116 
with no loss to follow-up concerning the primary objective.  
Another advantage to using a national registry as a trial platform is the ability to follow 
patients for life by merging with other health registries. A limitation relates to non-
adjudicated secondary outcome events. Therefore, total mortality was chosen as the primary 
objective which does not require adjudication. Any degree of uncertainty in other non-
adjudicated secondary outcome variables should be equally distributed over the two 
randomized study groups. Furthermore, the agreement between key variables in the registry 
and medical records has repeatedly been found to be 95% to 96% when checked by 
designated registry monitors in the past.92 
In summary, RRCTs should be used complementary to regular RCTs and are most suitable 
for simple, but clinically relevant, issues regarding treatments already used in daily practice 
for which there are lack of incentives for industry sponsorship due to low potential for 
payback.117 A valid hard endpoint with a high degree of completeness should be used as the 
primary endpoint.  
Everything mentioned above considered, the assessment of the routine use of supplemental 
oxygen in patients with suspected AMI evaluated by mortality was ideal for an RRCT. 
 
6.4 STUDY POPULATION WITH SUSPECTED AMI - WHY INCLUDE SO 
BROADLY? 
In the TASTE trial,90 only patients with STEMI were included by dedicated interventional 
cardiologists at the cath lab when diagnosis was confirmed. Even in the most recent trials on 
oxygen in AMI,82,86 only STEMI patients were recruited by the ambulance service. There 
might be various explanations for this selection. Among those may be: STEMI as being 
considered the most acute presentation of ACS, a more homogenous pathophysiology, well-
established logistics and a smaller group of caregivers involved in initial care, easier 
diagnosis with clear ECG findings and often pronounced symptomatology.  
In the present study, we extended the concept by including a broader population with 
suspected AMI recruited at first medical contact (ambulance service, ED, CCU, cath lab) 
engaging several different professions (physicians, nurses, paramedics) in patient selection, 
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randomization and trial procedures. Obviously, this led to much more complicated logistics 
and demands for education and support of the different participating individuals and units, 
thus emphasizing the need for a stringent national and local trial organization. On the positive 
side, this design allowed us to assess patients outside the STEMI group who nowadays are 
more numerable and often come with a more complicated presentation and more severe long-
term prognosis. Hereby, DETO2X-AMI was intended to mirror the real-world daily situation 
clinicians face all over the world and allow us to give a more generalizable treatment 
recommendation.  
Furthermore, even the clinical routine of supplying oxygen at first medical contact demanded 
patient recruitment this way. Otherwise, many patients would have been non-eligible due to 
early initiated oxygen therapy.  
Moreover, it enabled assessment of a real ITT population which we believed was more 
correct than selecting patients as eligible at cathlab as was done in AVOID,82,85 thereby 
excluding 31% of randomized patients and introducing the risk of bias.  
On the negative side, we mixed the primary group of interest - AMI patients in general and 
STEMI patients in particular - with patients who suffered from other conditions than ACS. 
Planned subgroup analysis will supply more detailed data on all the groups mentioned. 
 
6.5 OXYGEN THERAPY IN SPECIFIC RISK GROUPS  
Although oxygen therapy was found to be of neutral effect in the general population with 
suspected AMI,102 it is of importance to analyze groups with specific risks separately. As 
shown in chapter 5.2, we evaluated patients with and without confirmed AMI and different 
infarction types, males and females, different age groups, patients with known cardiovascular 
risk factors such as smokers, diabetics, patients with chronic kidney disease or anemia, and 
patients with higher or lower initial oxygen saturation or previous cardiovascular disease.  
When assessing the primary endpoint of death within one year, the neutral results remained 
unchanged throughout these prespecified subgroups. These findings may suggest that oxygen, 
although undoubtedly a potent drug, has limited overall cardiovascular effects when 
administered to normoxemic patients at a moderate dose and for a relatively short time.  
The most compelling subgroup is the 1,062 individuals with an initial oxygen saturation 
below 95% in which there was a non-significant trend to the benefit of oxygen 
supplementation. However, our trial was not powered to assess the ideal saturation cutoff 
value around 90%, and therefore, future research must determine the ideal lower limit for the 
initiation of oxygen therapy.  
Another risk group of interest are patients with chronic obstructive pulmonary disease 
(COPD). As COPD is not a parameter in SWEDEHEART, it must be obtained from the 
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Swedish National Inpatient and Outpatient Registries with a delay of up to 12 months and is 
therefore not yet available. 
 
6.6 RESEARCH IN ACUTE CARDIAC CARE: SOME ETHICAL ASPECTS 
CONCERNING INFORMED CONSENT 
There are multiple ethical issues when performing cardiovascular research, especially in the 
acute setting.118 Adequate informed consent is a fundamental part of the ethical conduct of 
research and historically based on the Nuremberg Code.119 The ideal conditions under which 
consent should be obtained include a calm environment where thorough information can be 
given repeatedly, presented in writing and/or other multimedia platforms so that the patient 
and the responsible physician or investigator can establish a relationship of trust. Time and 
opportunity for questions and discussion ought to be provided generously. However, the 
circumstances in acute clinical trials often make it difficult to fulfill these demands.  
When full informed consent cannot be obtained, two other forms of consent can be applied: 
abbreviated consent and delayed consent.  
In our case, the ethical committee allowed us to use abbreviated informed consent (oral 
consent first and written confirmation as soon as possible after admission, described in detail 
in 4.3.2). Nevertheless, some observers had concerns that patients with ongoing acute 
myocardial infarction were not able to give any informed consent at all, not even in an 
abbreviated form, and questioned the validity of a statement given under such conditions. 
There is a risk that some patients may consent and subsequently withdraw, or vice versa; they 
may say no initially but after mature reflection may change their mind.  
Unfortunately, the complete truth remains unknown as these figures were not all obtained in 
our trial. We know that in total, 403 (6.1%) patients changed their mind refusing to continue 
participation, most commonly in the oxygen group declining to continue oxygen therapy.  
Further, although unconsciousness was an exclusion criterion in our trial, patients frequently 
suffered from multiple symptoms like pain, stress, sickness or anxiety, and some investigators 
might have felt that it was inappropriate to burden a patient in such a situation with even a 
brief discussion about a research trial on top of all the difficulties they were already facing. 
The number of patients regretting to have declined participation is unknown. Undoubtedly, 
this led to a selection of patients who were usually younger, healthier and more vocal than the 
general AMI population which also explains to some extent the lower event rate discussed in 
detail in chapter 5.2.  
Another option is the delayed consent form where eligible patients are recruited without prior 
knowledge and asked to provide consent retrospectively during the admission period. 
Advantages are obvious: A faster and more comprehensive recruitment of a truly unselected 
study population as close as possible to the general population is achieved, providing data 
which can be more easily generalized to everyday patient care. On the downside, patients can 
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be unwilling to participate and refuse consent. A special problem can arise if a patient dies 
prior to being able to give or withdraw consent. Concerning this issue, some countries like the 
UK have introduced a special central ethics body where applications for approval for the use 
of clinical data from patients who died soon after presentation are evaluated. Alternatively, it 
can be necessary to approach relatives which can be troublesome at a time of grief discussing 
a complex concept that is difficult for them to grasp. 
In summary, research in the field of acute cardiovascular disease is problematic. There is no 
concept that fits all trials, and a difficult balance between obtaining ideal data and ensuring 
protection of the patients’ ethical demands must be kept. Clinical equipoise, defined by 
Freedman 1987120 as the genuine uncertainty in the expert medical community over whether 
a treatment will be beneficial or not, underlies this decision. If studying two treatments 
already in routine use, applied within their licensed indication and dosing, both abbreviated 
consent and delayed consent could be considered. Delayed informed consent is currently not 
allowed in conscious patients in Sweden, disqualifying it as an option in the DETO2X trial. 
However, in the latest version of the Declaration of Helsinki,88 section 30, specific provisions 
are made for studies in the acute setting which might be used in the line of reasoning when 
applying for studies in the future. Led by the UK Health Research Authority a framework 
was developed which can be used as a practical guide for those developing or reviewing 
research in the emergency setting.121  
 
6.7 CLINICAL IMPLICATIONS 
When we were planning this trial series in 2010/2011, supplemental oxygen was still an 
essential part of supportive care to all patients with suspected AMI irrespective of oxygen 
saturation level. During the course of the trial, attitudes and even guidelines changed 
gradually to a more cautious approach concerning the use of oxygen, for example by 
introducing an arbitrary lower limit of <95% for commencing therapy in the ESC STEMI 
guidelines 2012,8 and/or adding clinical findings such as respiratory distress.7 However, these 
adjustments were still all based on expert opinion (level of evidence C).  
With the DETO2X-AMI study we could deliver sound evidence based on good quality data 
from a large randomized trial that patients with suspected AMI without hypoxemia at 
baseline do not benefit from routine oxygen therapy.102 Already, some experts call for a 
change of clinical practice to reflect this new evidence.122 The new has already been 
recognized by the ESC Task force who changed their recommendation for supplemental 
oxygen in the 2017 STEMI guidelines based on our trial.123 The interest in our findings 
across the world has been immense and there is a good chance that other future guidelines 
and, subsequently, clinical practice might follow ESCs example.   
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6.8 REMAINING QUESTIONS AND FUTURE RESEARCH 
In this thesis, we showed that routine oxygen therapy in non-hypoxemic patients with 
suspected AMI had no effect on either hard clinical endpoints or infarct size, nor did it affect 
markers of inflammation in an AMI subgroup. Although our findings do not support the 
general use of oxygen in the normoxemic patient with suspected AMI, there might be 
subgroups of patients at risk - both of hypoxemia or hyperoxemia. Further subgroup analysis 
and substudies from our trial might add additional information on a more detailed level.  
For example, in patients with STEMI, the effects of oxygen on PCI associated outcomes are 
of great interest as hyperoxemia-induced vasoconstriction45 might enhance the risk of stent 
undersizing and subsequent complications such as in-stent restenosis and stent thrombosis76,77 
We aim to assess these latter complications in a future subgroup analysis. Adding 
rehospitalization for heart failure to a composite endpoint will add power to the primary 
analysis and possibly clarify indications.  
Nevertheless, uncertainty remains concerning the ideal cut-off to initiate supplemental 
oxygen, dosage and duration of therapy. These questions have not been addressed in the 
published trials including ours, and further hypothesis testing in new trials is warranted. For 
example, is there a lower threshold that we should accept in certain diagnoses, certain risk 
groups or accompanying clinical findings? This remains uncertain and the question is an 
important potential area for new RCTs, as subgroups in the trials mentioned above are 
unlikely to provide further insight given the enrolment oxygen saturation.  
 
Figure 15: Illustration of potential risk-benefit ratio of oxygen treatment in acute 
cardiovascular conditions, including recently published RCTs and ESC STEMI guidelines 
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Finally, oxygen saturation is not static so further studies may want to explore a titration above 
some threshold rather than a fixed dose of oxygen. Automated devices are already available 
that may alleviate administration and liberate health care personnel but risks such as masking 
of clinical deterioration with desaturation as a warning sign must be considered.124 Ranchord 
and others performed a RCT on titrated versus high flow oxygen but did not have the power 
to look at hard clinical endpoints.81 Taking in our results, I would rather compare titrated 
oxygen versus ambient air. However, considering the expected low effect difference, a very 
large multicenter (R) RCT would be necessary which will be exceedingly difficult to 
perform. 
Furthermore, our insights could be applied on other groups of patients. Oxygen in heart 
failure is already frequently discussed,38 and several research collaborations hope to launch a 
trial in the near future.  
In patients with cerebrovascular disease – ischemic stroke in particular – oxygen therapy has 
also been widely used without clear evidence. Recently, the results from the multicenter 
Stroke Oxygen Study from the United Kingdom were published. There, 8003 patients with 
acute stroke were randomized 1:1:1 to continuous oxygen for 72 hours, nocturnal oxygen for 
3 nights, or ambient air. Routine prophylactic low-dose oxygen therapy given via nasal tubes 
at 3 liters/min did not improve outcome among patients who were not hypoxemic at baseline, 
regardless if oxygen was given continuously for 72 hours or at night only. This applied to the 
primary endpoint of 90-day functional outcome and secondary outcome measures, including 
early neurological recovery, mortality, disability, independence in basic and extended 
activities of daily living, and quality of life.125 It is a fair guess that recommendations for 
oxygen supplementation in patients with acute stroke may change accordingly based on these 
results.  
Even in critically ill patients in postcardiac arrest, sepsis, or traumatic brain injury, the 
importance of individualized oxygen therapy to avoid hyperoxemia has been proposed126 and 
should be evaluated in future trials.  
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6.9 LIMITATIONS 
Several limitations to the concept and our studies should be noted.  
General limitations of the RRCT design are discussed above in section 6.3. 
Study II used a prospective randomized open blinded endpoint (PROBE) assessment.127 
Generally, the strength of this method is that due to the lack of blinding of investigators and 
patients the conduct of the trial is simplified and reflects routine medical practice far better. 
However, this simplification comes at a price; the risk of bias remains.128 Double blinding 
was not feasible for practical reasons as there is no pressurized air in Swedish ambulances. 
Most units use closed Hudson masks which would have put patients at risk of carbon dioxide 
retention if only used as sham comparator.  
When planning the trial, the sources available suggested a 1-year mortality of around 12% in 
patients with confirmed AMI. A 20% increased risk would have resulted in a mortality of 
14.4% in the group assigned to ambient air which was used for power calculations described 
earlier (chapter 4.6.4). The actual power to detect a 20% reduction in mortality was 
approximately 55%, clearly lower than the intended 90%. The main explanation for that is 
that we overestimated the mortality rate in the target population eligible for enrolment. There 
are various possible explanations for this discrepancy: First, we underestimated the risks 
involved with hypoxemia at presentation. Unfortunately, since we have no data on oxygen 
saturation in the SWEDEHEART registry, we had no possibility to estimate in our sample 
size calculation the proportion of AMI patients who were hypoxemic at presentation, and the 
mortality rate among those. These patients were excluded from our trial by design, yet they 
contribute substantially to the total mortality in the unselected AMI population as shown. 
Second, the informed consent procedure sanctioned by the ethical committee demanded oral 
agreement prior to study initiation. Therefore, patients with altered conscious state, 
comprehension difficulties or communication problems were not eligible for the trial; they 
constitute a larger group than expected posing a significant disease burden. This poses a 
common challenge as discussed above (discussion, page 43 and 44). 
As evident from chapter 5.2, the AMI population not enrolled in the DETO2X study had a 
high mortality of 16%. In fact, the one-year all-cause mortality in the combined ITT-
population and non-DETO2X AMI population was 13%, close to our original estimation in 
our power calculation. Furthermore, patients were more frequently admitted for dyspnea 
(8.8% vs 1.5%) or due to cardiac arrest (2.5% vs 0%). Thus, the exclusion of hypoxemic 
patients and patients otherwise not eligible had greater impact on one-year mortality than we 
anticipated. Given a one-year mortality rate of 5%, to detect a 20% reduction in mortality 
with 90% power would have required 16,167 patients which was not feasible to obtain. 
Although we consider the point estimate of 0.97, the superimposable mortality curves and the 
consistent findings in all subgroup analyses indicative of a neutral effect of oxygen on 
mortality, we cannot with 95% confidence rule-out a positive or negative effect of oxygen on 
mortality of just above 20%. 
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The results and conclusions of study III are drawn from a prespecified subgroup analysis and 
should therefore be interpreted with caution. First, the proximity extension assay technology 
does not allow absolute quantification of the proteins obtained, and there is a lack of 
systematic comparison with results from standard cytokine measurement methods, like 
ELISA129 or Luminex.130 Secondly, follow-up blood samples were restricted to 5-7 h. As has 
been reported from experimental AMI models, an increase in IL-10 is expected to occur at a 
later stage of the inflammatory response.131 We cannot exclude that oxygen treatment affects 
the balance between pro- and anti-inflammatory cytokines at a later stage of the systemic 
inflammatory response to AMI. Prolonged induction of pro-inflammatory signaling following 
AMI has been associated with poor prognosis.27 However, the findings that 6-12 h oxygen 
therapy did not hamper the 1-year prognosis102 may counter the assertion that supplemental 
oxygen has clinically relevant detrimental effects on the inflammatory response at a later time-
point. 
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7 SUMMARY AND CONCLUSION 
 
The design of the DETO2X-AMI-trial was found to be robust, feasible and safe. Inclusion 
criteria managed to identify high-risk individuals with acute cardiac disease with a high 
proportion of acute myocardial infarctions among the study population. 
Patients with suspected AMI who did not have hypoxemia at baseline did not benefit from 
routine oxygen therapy when assessing all-cause mortality, rehospitalization with AMI or 
infarct size by biomarkers. Neither did we find indication of harm when evaluating the same 
endpoints.  
Furthermore, when studying supplemental oxygen with regard to the systemic inflammatory 
response to AMI, no impact on the early release of systemic inflammatory markers could be 
shown.  
In summary, our findings do not support the general use of oxygen in normoxemic patients 
with suspected AMI. Nevertheless, the risk to develop hypoxemia remains which must be 
detected and treated immediately. Although we could not demonstrate deleterious effects of 
routine oxygen treatment, there might be a dose-dependent relationship, and inadvertent 
hyperoxemia should be avoided. 
  
Svensk Sammanfattning 
   
DETO2X-AMI │ 50 
8 SVENSK SAMMANFATTNING 
 
Bakgrund 
Syrgas är sedan många år en etablerad del i behandlingen av patienter med misstänkt 
hjärtinfarkt. Aktuell behandlingsrekommendation enligt internationella riktlinjer, är att ge 
syrgas vid akut koronart syndrom för att korrigera låg syremättnad (<90%). För patienter med 
syremättnad ≥90% finns inga enhetliga rekommendationer då det här råder brist på 
vetenskaplig dokumentation. Mot bakgrund av hur utbredd syrgasbehandling är, i Sverige 
och i övriga världen, finns det ett stort behov att tydliggöra syrgasens roll vid behandling av 
misstänkt akut hjärtinfarkt. 
Den bakomliggande hypotesen är att ökad syretillförsel minskar hjärtinfarktens storlek 
genom ökad leverans av syre till hotade områden i hjärtmuskeln. Genom begränsning av 
infarktstorlek minskar risken för utveckling av komplikationer som hjärtsvikt och 
hjärtrytmrubbningar vilket därmed kan förbättra prognosen. Befintlig vetenskaplig 
dokumentation ger ett visst stöd för denna hypotes, men den baseras på äldre, mindre studier.  
Resultat från experimentella studier har visat att hyperoxi, alltså syremättnad över den 
normala, kan ha negativa effekter för hjärta och blodkärl. Detta kan t.ex. ske via 
kärlsammandragning, resulterande i reducerat blodflöde i kranskärlen och produktion av 
reaktiva syreradikaler. Dessa kan leda till en rubbad balans i kroppens antioxidativa försvar 
och därigenom resultera i ökad hjärtmuskelskada via cellsvullnad, programmerad celldöd och 
aktivering av inflammatoriska processer.  Huruvida syrgasbehandling och dess effekter har 
betydelse för det kliniska utfallet vid hjärtinfarkt är inte tidigare studerat. 
 
Målsättning 
Syftet med denna avhandling var att bygga upp en nationell studieorganisation med hjälp av 
ett väletablerat kvalitetsregister inom krankärlssjukdom, SWEDEHEART. Efter att ha testat 
studiekonceptet i en pilotstudie (delarbete 1) utökades konceptet till hela riket (delarbete 2) 
för att analysera kliniska utfallsmått såsom mortalitet. I en prespecifierad substudie 
undersöktes syrgasbehandlingens eventuella effekter på systemisk inflammation med analys 
av biomarkörer (delarbete 3).  
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Metod och resultat 
Studie I 
Studie I är en pilotstudie utförd på Södersjukhuset i Stockholm, där patienter med misstänkt 
hjärtinfarkt rekryterades i ambulans, på akutmottagningen, på hjärtintensivvårdsavdelningen 
eller i samband med akut kranskärlsröntgen.  Inklusionskriterier var följande: ålder minst 30 
år, symtom som ingav misstanke om hjärtinfarkt (bröstsmärta eller andnöd) under kortare tid 
än sex timmar, en syremättnad på 90% eller mer samt antingen EKG förändringar med tecken 
på ischemi (syrebrist i hjärtat) eller ett blodprov med förhöjd hjärtskademarkör. Efter 
muntligt samtycke lottades patienterna till att antingen erhålla syrgas via andningsmask (6 L/ 
min) i 6-12 timmar eller till att andas omgivande luft.  
Under tre månader inkluderades 129 patienter med misstänkt hjärtinfarkt och normal 
syresättning i blodet. Av dessa hade 81 (63%) patienter hjärtinfarkt (53% icke-ST-
höjningsinfarkt, 47% ST-höjningsinfarkt). Trettiotvå (25%) patienter diagnosticerades med 
annan akut hjärtsjukdom. Sexton (12%) patienter fick diagnosen “ospecificerad bröstsmärta”.  
Inga betydande logistiska eller medicinska problem förekom. Syrgasbehandlingen i 12 
timmar tolererades väl. Vid 30 dagars uppföljning hade 3 patienter (4.6%) i luftgruppen 
avlidit, inga dödsfall hade förekommit i syrgasgruppen (p=0.12, ej signifikant).  
 
Studie II 
Med studie I som bas genomfördes studie II som en registerbaserad randomiserad klinisk 
studie i hela Sverige. Av de 69 sjukhus i landet som har en möjlighet att följa upp patienter 
med hjärtinfarkt deltog 35. Det nationella kvalitetsregistret SWEDEHEART användes för att 
ta fram resultat gällande studierelaterade processer. Data för det primära utfallsmåttet, total 
mortalitet inom ett år, inhämtades ifrån Folkbokföringsregistret.  
Mellan april 2013 och december 2015 inkluderades 6629 patienter med misstänkt 
hjärtinfarkt. Ambulanstransport skedde i 67% av fallen. Tiden från symtomdebut till 
randomisering var i genomsnitt fyra timmar i båda grupperna. Av samtliga patienter som 
deltog i studien erhöll 75% diagnosen akut hjärtinfarkt vid utskrivningen från sjukhus. 
Dödligheten under ett år var 5.0% bland patienter som behandlades med syrgas och 5.1% 
bland patienter som fick enbart luft, därmed påvisades ingen signifikant skillnad. 
Återinläggning på sjukhus på grund av hjärtinfarkt förekom i 3.8% av fallen som behandlades 
med syrgas och i 3.3% av fallen som behandlades med luft. Inte heller detta är en signifikant 
skillnad. Blodprovet med hjärtskademarkör troponin T, som är ett mått på 
hjärtmuskelskadans omfattning, skilde sig inte heller mellan grupperna. 
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Studie III 
Studie III är en substudie till studie II som genomfördes på Södersjukhuset, Stockholm och 
på Universitetssjukhuset Linköping. Mellan november 2014 och december 2015 inkluderades 
144 patienter med bekräftad akut hjärtinfarkt, varav 76 (53%) randomiserades till syrgas och 
68 (47%) till omgivande luft. Blodprover togs direkt efter randomisering samt efter 5-7 
timmar. Primära utfallsmått var syrgasens effekt på systemisk inflammation mätt som 
förändring av inflammationsmarkörer mellan de två blodproven. Med en så kallad ”proximity 
extension assay technology”, som möjliggör analyser av ett stort antal biomarkörer samtidigt, 
analyserades 92 olika inflammationsmarkörer. 
Vid analysen av förändring mellan blodprov vid baseline och efter 5-7 timmar visade 8 
markörer (IL-6, ST1A1, IL-8, VEGF-A, CD40, CCL23, PD-L1, and CSF-1) signifikant 
ökade nivåer och 13 markörer (TRAIL, CXCL11, TRANCE, CCL19, Flt3L, CXCL6, HGF, 
CCL25, CXCL10, TWEAK, CXCL9, IL-10, and OSM) signifikant reducerade nivåer. 
Medianvärdet för hjärtskademarkören, högkänsligt troponin T, var 52.9 ng/L hos patienter i 
syrgasgruppen och 63.3 ng/L hos patienter i luftgruppen. Efter 5-7 timmar ökade värdet till 
1436 ng/L och 1574 ng/L i respektive grupperna, ledande till en medianskillnad på 1403 ng/L 
och 1238 ng/L (p= 0.696), en icke-signifikant skillnad.  
Efter justering för den relativa ökningen av troponin T över tid samt ålder och kön som 
potentiella störfaktorer förelåg ingen skillnad i den systemiska inflammationsreaktionen 
mellan de som fick syrgasbehandling och de som fick omgivande luft. 
 
Sammanfattning och slutsatser 
Studie 1 kunde genomföras utan att större logistiska eller medicinska problem uppkom och 
studiekonceptet bedömdes genomförbart och säkert. Inklusionskriterierna identifierade i hög 
utsträckning hjärtinfarktpatienter som kunde rekryteras i studien. En välfungerande hemsida 
som studieplattform för kommunikation och utbildning utvecklades.  
Studie 2 genomfördes som en pragmatisk, nationell, registerbaserad, randomiserad klinisk 
studie. Vi fann inga gynnsamma eller negativa effekter av syrgasbehandling med avseende på 
dödlighet under ett år, återinläggning för hjärtinfarkt eller utbredning av hjärtmuskelskada. 
I studie 3 undersökte vi om syrgasbehandling har effekt på den systemiska 
inflammationsprocessen utlöst av en akut hjärtinfarkt. Vi fann inga tecken till att 
syrgasbehandling påverkar denna reaktion.  
Sammanfattningsvis finner vi inga belägg för att syrgasbehandling är gynnsam eller skadlig 
för patienter utan hypoxi (syrebrist) vid akut hjärtinfarkt. Därmed finns det nu underlag för att 
sluta använda syrgasbehandling i denna patientpopulation vilket redan har lett till en 
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uppdatering i europeiska behandlingsrekommendationer för patienter med akut ST-
höjningsinfarkt.  
Behovet av monitorering av syremättnad kvarstår dock då hypoxi kan tillkomma under 
akutskedet vid hjärtinfarkt och ska då behandlas utan dröjsmål. Även om negativa effekter av 
hyperoxemi ej kunde påvisas utesluter detta ej att det kan föreligga risker med större mängder 
syrgas, varför detta bör undvikas. 
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